Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Kefeli U, et al. Among authors: ciltas a. Oncol Lett. 2013 Aug;6(2):605-611. doi: 10.3892/ol.2013.1408. Epub 2013 Jun 17. Oncol Lett. 2013. PMID: 24137379 Free PMC article.
Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
Kefeli U, Buyuberber S, Akyol M, Yildiz R, Kaplan MA, Ciltas A, Sevinc A, Karaca H, Seker M, Ozdemir N, Alacacioglu A, Coskun U, Isikdogan A, Dane F, Gumus M, Ozkan M, Suner A, Tarhan MO, Benekli M. Kefeli U, et al. Among authors: ciltas a. Hepatogastroenterology. 2013 Jun;60(124):647-52. doi: 10.5754/hge12692. Hepatogastroenterology. 2013. PMID: 23165189
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Yildiz R, et al. Among authors: ciltas a. J Cancer Res Clin Oncol. 2012 Nov;138(11):1845-52. doi: 10.1007/s00432-012-1264-5. Epub 2012 Jun 22. J Cancer Res Clin Oncol. 2012. PMID: 22722713
Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O, Karaca H, Ciltas A, Kaplan MA, Benekli M, Sevinc A, Demirci U, Eren T, Kodaz H, Isikdogan A, Ozkan M, Buyukberber S. Bozkurt O, et al. Among authors: ciltas a. Asian Pac J Cancer Prev. 2014;15(4):1845-9. doi: 10.7314/apjcp.2014.15.4.1845. Asian Pac J Cancer Prev. 2014. PMID: 24641419 Free article.
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, Yazilitas D, Ulas A, Kucukoner M, Aksoy A, Demirci U, Uysal M, Tanriverdi O, Gunaydin Y, Sumbul AT, Yildiz R, Karaca H, Oksuzoglu B, Ciltas A, Buyukberber S, Benekli M; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: ciltas a. Breast. 2016 Feb;25:22-6. doi: 10.1016/j.breast.2015.11.006. Epub 2015 Dec 20. Breast. 2016. PMID: 26801412
Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).
Aydin D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, Bilir C, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M. Aydin D, et al. Among authors: ciltas a. J BUON. 2016 Sept-Oct;21(5):1242-1249. J BUON. 2016. PMID: 27837629 Free article.
Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Inal A, Ciltas A, Yildiz R, Berk V, Kos FT, Dane F, Unek IT, Colak D, Ozdemir NY, Buyukberber S, Gumus M, Ozkan M, Isikdogan A. Inal A, et al. Among authors: ciltas a. Asian Pac J Cancer Prev. 2012;13(5):1841-4. doi: 10.7314/apjcp.2012.13.5.1841. Asian Pac J Cancer Prev. 2012. PMID: 22901133 Free article.
Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
Bozkurt O, Inanc M, Hacibekıroglu I, Esbah O, Seker M, Ulas A, Aydin K, Uysal M, Kücüköner M, Uncu D, Cıltas A, Unal OÜ, Durnali A, Demırcı U, Berk V, Tonyali O, Oksüzoglu B, Karaca H, Ozkan M. Bozkurt O, et al. Among authors: ciltas a. Anticancer Res. 2014 Aug;34(8):4463-70. Anticancer Res. 2014. PMID: 25075086
Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.
Özaslan E, Karaca H, Koca S, Sevinç A, Hacioğlu B, Özkan M, Özçelik M, Duran AO, Hacibekiroğlu İ, Yildiz Y, Tanriverdi Ö, Menekşe S, Aksoy A, Bozkurt O, Urvay S, Uysal M, Demir H, Çiltaş A, Dane F. Özaslan E, et al. Among authors: ciltas a. Anticancer Drugs. 2017 Feb;28(2):222-229. doi: 10.1097/CAD.0000000000000445. Anticancer Drugs. 2017. PMID: 27768606
33 results